Assessing cardiac, hepatic, and renal safety of hospitalized Covid-19 patients treated with: remdesivir: a retrospective cohort study.

Abstract

Remdesivir played a major part as a treatment possibility of Covid-19 patients and still is part of treatment guidelines, however, there still are cardiac, hepatic, and renal safety concerns. The main aim of this research was to investigate cardiac-, hepatic and renal-related safety concerns in Covid-19 patients treated with remdesivir. To investigate these safety outcomes a retrospective cohort study was conducted. We included 2554 patients (male: 1449; female: 1105, remdesivir: 584; no-remdesivir: 1970) from the Haga Hospital, Leiden University Medical Center (LUMC), Alrijne Hospital and Haaglanden Medical Center (HMC) from the first of March 2020 until the first of March 2021. Bradycardia was seen in 8.3% of the remdesivir users compared to 6.1% in the no-remdesivir users (OR: 1.21; 95% CI: 0.80-1.83, p= 0.370). Acute kidney injury (AKI) was seen in 4.2% of the remdesivir users in comparison to 5.3% in noremdesivir users (OR: 0.93; 95% CI: 0.54-1.59, p= 0.778). Acute liver injury was seen in 4.3% of the remdesivir users and in 1.1% of the no-remdesivir users (OR: 3.06; 95% CI: 1.62-5.76, p<0.001). Based on these findings there is no need to be concerned about the cardiac and renal outcomes of remdesivir. However, remdesivir still is associated with a higher likelihood on the occurrence of ALI.